Invention Grant
- Patent Title: Beta-amino-isoquinolinyl amide compounds
-
Application No.: US15476850Application Date: 2017-03-31
-
Publication No.: US09963432B2Publication Date: 2018-05-08
- Inventor: Jill M. Sturdivant , Mitchell A. deLong , Susan M. Royalty
- Applicant: Aerie Pharmaceuticals, Inc.
- Applicant Address: US NC Durham
- Assignee: Aerie Pharmaceuticals, Inc.
- Current Assignee: Aerie Pharmaceuticals, Inc.
- Current Assignee Address: US NC Durham
- Agency: K&L Gates LLP
- Agent Louis C. Cullman; Benjamin D. Heuberger
- Main IPC: C07D217/24
- IPC: C07D217/24 ; C07D217/22

Abstract:
Disclosed are alpha-aryl-beta-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing isoquinoline amide compounds.
Public/Granted literature
- US20180050990A1 BETA-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS Public/Granted day:2018-02-22
Information query